Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis - PubMed (original) (raw)
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis
R A Slayden et al. Mol Microbiol. 2000 Nov.
Free article
Abstract
Genetic and biochemical evidence has implicated two different target enzymes for isoniazid (INH) within the unique type II fatty acid synthase (FAS) system involved in the production of mycolic acids. These two components are an enoyl acyl carrier protein (ACP) reductase, InhA, and a beta-ketoacyl-ACP synthase, KasA. We compared the consequences of INH treatment of Mycobacterium tuberculosis (MTB) with two inhibitors having well-defined targets: triclosan (TRC), which inhibits InhA; and thiolactomycin (TLM), which inhibits KasA. INH and TLM, but not TRC, upregulate the expression of an operon containing five FAS II components, including kasA and acpM. Although all three compounds inhibit mycolic acid synthesis, treatment with INH and TLM, but not with TRC, results in the accumulation of ACP-bound lipid precursors to mycolic acids that were 26 carbons long and fully saturated. TLM-resistant mutants of MTB were more cross-resistant to INH than TRC-resistant mutants. Overexpression of KasA conferred more resistance to TLM and INH than to TRC. Overexpression of InhA conferred more resistance to TRC than to INH and TLM. Co-overexpression of both InhA and KasA resulted in strongly enhanced levels of INH resistance, in addition to cross-resistance to both TLM and TRC. These results suggest that these components of the FAS II complex are not independently regulated and that alterations in the expression level of InhA affect expression levels of KasA. Nonetheless, INH appeared to resemble TLM more closely in overall mode of action, and KasA levels appeared to be tightly correlated with INH sensitivity.
Similar articles
- Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.
Larsen MH, Vilchèze C, Kremer L, Besra GS, Parsons L, Salfinger M, Heifets L, Hazbon MH, Alland D, Sacchettini JC, Jacobs WR Jr. Larsen MH, et al. Mol Microbiol. 2002 Oct;46(2):453-66. doi: 10.1046/j.1365-2958.2002.03162.x. Mol Microbiol. 2002. PMID: 12406221 - Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria.
Kremer L, Dover LG, Morbidoni HR, Vilchèze C, Maughan WN, Baulard A, Tu SC, Honoré N, Deretic V, Sacchettini JC, Locht C, Jacobs WR Jr, Besra GS. Kremer L, et al. J Biol Chem. 2003 Jun 6;278(23):20547-54. doi: 10.1074/jbc.M302435200. Epub 2003 Mar 24. J Biol Chem. 2003. PMID: 12654922 - Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB.
Schaeffer ML, Agnihotri G, Volker C, Kallender H, Brennan PJ, Lonsdale JT. Schaeffer ML, et al. J Biol Chem. 2001 Dec 14;276(50):47029-37. doi: 10.1074/jbc.M108903200. Epub 2001 Oct 12. J Biol Chem. 2001. PMID: 11600501 - Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.
Unissa AN, Subbian S, Hanna LE, Selvakumar N. Unissa AN, et al. Infect Genet Evol. 2016 Nov;45:474-492. doi: 10.1016/j.meegid.2016.09.004. Epub 2016 Sep 6. Infect Genet Evol. 2016. PMID: 27612406 Review. - Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
Lu XY, You QD, Chen YD. Lu XY, et al. Mini Rev Med Chem. 2010 Mar;10(3):181-92. doi: 10.2174/138955710791185064. Mini Rev Med Chem. 2010. PMID: 20408801 Review.
Cited by
- Adenylating enzymes in Mycobacterium tuberculosis as drug targets.
Duckworth BP, Nelson KM, Aldrich CC. Duckworth BP, et al. Curr Top Med Chem. 2012;12(7):766-96. doi: 10.2174/156802612799984571. Curr Top Med Chem. 2012. PMID: 22283817 Free PMC article. Review. - Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia.
England K, am Ende C, Lu H, Sullivan TJ, Marlenee NL, Bowen RA, Knudson SE, Knudson DL, Tonge PJ, Slayden RA. England K, et al. J Antimicrob Chemother. 2009 Nov;64(5):1052-61. doi: 10.1093/jac/dkp307. Epub 2009 Sep 4. J Antimicrob Chemother. 2009. PMID: 19734171 Free PMC article. - Crystal structure and substrate specificity of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus.
Qiu X, Choudhry AE, Janson CA, Grooms M, Daines RA, Lonsdale JT, Khandekar SS. Qiu X, et al. Protein Sci. 2005 Aug;14(8):2087-94. doi: 10.1110/ps.051501605. Epub 2005 Jun 29. Protein Sci. 2005. PMID: 15987898 Free PMC article. - The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.
Kingry LC, Cummings JE, Brookman KW, Bommineni GR, Tonge PJ, Slayden RA. Kingry LC, et al. J Bacteriol. 2013 Jan;195(2):351-8. doi: 10.1128/JB.01957-12. Epub 2012 Nov 9. J Bacteriol. 2013. PMID: 23144254 Free PMC article. - Electrotransformation of Clostridium thermocellum.
Tyurin MV, Desai SG, Lynd LR. Tyurin MV, et al. Appl Environ Microbiol. 2004 Feb;70(2):883-90. doi: 10.1128/AEM.70.2.883-890.2004. Appl Environ Microbiol. 2004. PMID: 14766568 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous